DK1948259T3 - Acellulær bioabsorberbare vævsregenereringsmatrixer produceret ved inkubering af acellulære blodprodukter - Google Patents

Acellulær bioabsorberbare vævsregenereringsmatrixer produceret ved inkubering af acellulære blodprodukter Download PDF

Info

Publication number
DK1948259T3
DK1948259T3 DK06817419.2T DK06817419T DK1948259T3 DK 1948259 T3 DK1948259 T3 DK 1948259T3 DK 06817419 T DK06817419 T DK 06817419T DK 1948259 T3 DK1948259 T3 DK 1948259T3
Authority
DK
Denmark
Prior art keywords
regeneration matrix
regeneration
matrix
cells
tissue
Prior art date
Application number
DK06817419.2T
Other languages
English (en)
Inventor
Jan-Eric W Ahlfors
Original Assignee
Genesis Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesis Tech Ltd filed Critical Genesis Tech Ltd
Application granted granted Critical
Publication of DK1948259T3 publication Critical patent/DK1948259T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3616—Blood, e.g. platelet-rich plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/38—Materials or treatment for tissue regeneration for reconstruction of the spine, vertebrae or intervertebral discs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)

Claims (23)

1. Acellulær bioabsorberbar regenereringsmatrix afledt fra blod og opnåelige ved en fremgangsmåde ifølge et hvilket som helst af kravene 14 til 19, matrixen omfatter: a) aggregater af sfæriske strukturer der er mindst 100 nm i diameter; og b) en proteinøs kerne med et proteinindhold på mindst 1%; hvor matrixen mangler væsentlig metabolisk aktivitet sammenlignet med den initielt til stede i dette blod; og yderligere hvor matrixen er i stand til at initiere vævsregenerering hos et individ med vævsskade, øge vævsregenerering hos et individ med vævsskade, eller begge.
2. Acellulær bioabsorberbar regenereringsmatrix ifølge krav 1, omfattende fibre blandet mellem aggregaterne.
3. Acellulær bioabsorberbar regenereringsmatrix ifølge krav 1 eller 2, hvor matrixen er selvanordnet.
4. Acellulær bioabsorberbar regenereringsmatrix ifølge et hvilket som helst af kravene 1-3, yderligere omfattende ét eller flere proteiner valgt fra gruppen bestående af: transferrin, serumalbumin, serumalbuminprecursor, komplement komponent 3, kæde A-D hemoglobin, IgM, IgGl, medullasin-inhibitor 2, carbonsyreanhydrase, CA1 protein, og kombinationer deraf.
5. Acellulær bioabsorberbar regenereringsmatrix ifølge et hvilket som helst af kravene 1-4, hvor de sfæriske strukturer genkendes af CD56-antistoffer.
6. Acellulær bioabsorberbar regenereringsmatrix ifølge et hvilket som helst af kravene 1-5, yderligere omfattende ét eller flere terapeutiske midler.
7. Acellulær bioabsorberbar regenereringsmatrix ifølge krav 6, hvor det ene eller flere terapeutiske middel er valgt fra gruppen bestående af: proteiner, peptider, lægemidler, cytokiner, ekstracellulære matrixmolekyler, vækstfaktorer, og kombinationer deraf.
8. Acellulær bioabsorberbar regenereringsmatrix ifølge krav 6 eller 7, hvor det ene eller flere terapeutiske midler er er fordelt heterogent i den acellulære bioabsorberbare regenereringsmatrix.
9. Acellulær bioabsorberbar regenereringsmatrix ifølge krav 6 eller 7, hvor det ene eller flere terapeutiske midler er fordelt homogent i den acellulære bioabsorberbare regenereringsmatrix.
10. Acellulær bioabsorberbar regenereringsmatrix ifølge et hvilket som helst af kravene 7-9, hvor den acellulære bioabsorberbare regenereringsmatrix beskytter og/eller forøger én eller flere fordelagtige virkninger af det ene eller flere terapeutiske midler.
11. Kombination af (i) en acellulær bioabsorberbar regenereringsmatrix ifølge et hvilket som helst af kravene 1-10 og (ii) celler der er blevet podet eller blandet i matrixen efter den er blevet fremstillet eller mens den er blevet fremstillet.
12. Kombinationen ifølge krav 11, hvor cellerne er valgt fra gruppen bestående af: stamceller, progenitorceller, somatiske celler, og kombinationer deraf.
13. Acellulær bioabsorberbar regenereringsmatrix ifølge et hvilket som helst af kravene 1-10, eller kombinationen af et hvert af krav 11 og 12, hvor regenereringsmatrixen er i fast eller halv-fast form, i form af en tredimensionel matrix eller i form afen suspension.
14. Fremgangsmåde til fremstilling af acellulære bioabsorberbare regenereringsmatrixer omfattende trinnene at a) tilvejebringe en isoleret blodprøve; b) fjerne intakte celler fra prøven; c) tilsætte et procesmedium én eller flere gange valgt fra gruppen bestående af: under isolation af prøven, før fjernelsestrinnet, før inkubationstrinnet, og under inkubationstrinnet, til at tilvejebringe en flydende acellulær fraktion; d) inkubere den flydende acellulære fraktion i et inkubationskammer uden at ryste eller på anden vis forstyrre den acellulære prøve i 2 eller flere dage for at danne acellulære bioabsorberbare regenereringsmatrixer der mangler væsentlig metabolisk aktivitet; og e) isolere den acellulære bioabsorberbare regenereringsmatrix.
15. Fremgangsmåden ifølge krav 14, hvor prøven omfatter blod eller en blodfraktion, hvor blodfraktionen kan indeholde et buffy-coat-lag, der yderligere kan være et buffy-coat/blodplade-/plasmalag.
16. Fremgangsmåden ifølge krav 15, hvor prøven indeholder en antikoagulant.
17. Fremgangsmåden ifølge krav 15, hvor prøven er blod indeholdende klumper, og fremgangsmåden omfatter solubilisering af klumperne.
18. Fremgangsmåden ifølge et hvilket som helst af kravene 14-17, hvor fjernelsen af intakte celler i b) udføres ved frysning, filtrering (fx gennem et størrelsesudvælgelsesfilter) og/eller centrifugering.
19. Fremgangsmåden ifølge krav 18, hvor størrelsesudvælgelsesfilteret udelukker partikler større end ca. 5 pm, større end ca. 1,2 pm, og/eller større end ca. 0,8 pm.
20. Anvendelse af den acellulære bioabsorberbare regenereringsmatrix ifølge et hvilket som helst af kravene 1-13 eller fremstillet ved fremgangsmåden ifølge et hvilket som helst af kravene 14-19, til fremstillingen af et medikament der er anvendt til at initiere, forøge, støtte, fremme, og/eller rette regenereringen af skadet, tabt, og/eller degenereret væv.
21. Anvendelse af den acellulære bioabsorberbare regenereringsmatrix ifølge et i hvilket som helst af kravene 1-13 eller fremstillet ved fremgangsmåden ifølge et hvilket som helst af kravene 14-19, til fremstillingen af et medikament til en terapifremgangsmåde omfattende initiering, øgning, modulering, fremme, støtte, og/eller dirigere én eller flere af de følgende processer: naturlig sårheling, vævsvækst, vævsfunktionalitet, automatisering af bevægemønstre, konnektivitet, i angiogenese, proliferering og/eller aktivering af progenitorceller, cellevækst og/eller proliferering, cellespecialisering og/eller brudforlængelse, dedifferentiering og/eller differentiering af celler, opregulering af cellulære gener relateret til regenerering, og/eller inhibering af ardannelse.
22. Anvendelse af den acellulære bioabsorberbare regenereringsmatrix ifølge et hvilket som helst af kravene 1-13 eller fremstillet ved fremgangsmåden ifølge et hvilket som helst af kravene 14-19, til fremstillingen af et medikament til stimulering af neurotrof aktivitet ved eller tæt ved et sted af skadet eller degenereret centralnervesystemsvæv, hvor neurotrofaktiviteten er kendetegnet i ved en stigning i ekspressionen på mindst ét neurotroft gen valgt fra gruppen bestående af: FGF-9, Netrin-1, NT-3, NCAM-15 GAP-43, og Neuregulin.
23. Farmaceutisk sammensætning til at fremme, dirigere, og/eller støtte sårheling og/eller vævsregenerering, vævsvækst, cellevækst, genopregulering, i celleinhibering, celleproliferering, cellededifferentiering, celledifferentiering, celletransdifferentiering, neuritfremvækst, genopregulering, én eller flere naturlig sårhelingsprocesser, eller kombinationer deraf, og/eller til stimulering af neurotrof aktivitet ved eller tæt ved et sted af skadet eller degenereret centralnervesystemsvæv, omfattende den acellulære bioabsorberbare regenereringsmatrix i ifølge et hvilket som helst af kravene 1-13 eller fremstillet ved fremgangsmåden ifølge et hvilket som helst af kravene 14-19.
DK06817419.2T 2005-10-26 2006-10-26 Acellulær bioabsorberbare vævsregenereringsmatrixer produceret ved inkubering af acellulære blodprodukter DK1948259T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73061405P 2005-10-26 2005-10-26
PCT/US2006/042016 WO2007050902A1 (en) 2005-10-26 2006-10-26 Acellular bioabsorbable tissue regeneration matrices produced by incubating acellular blood products

Publications (1)

Publication Number Publication Date
DK1948259T3 true DK1948259T3 (da) 2017-04-10

Family

ID=37763844

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06817419.2T DK1948259T3 (da) 2005-10-26 2006-10-26 Acellulær bioabsorberbare vævsregenereringsmatrixer produceret ved inkubering af acellulære blodprodukter

Country Status (11)

Country Link
US (3) US8268361B2 (da)
EP (1) EP1948259B1 (da)
JP (3) JP2016026184A (da)
AU (1) AU2006305989B2 (da)
CA (1) CA2627288C (da)
DK (1) DK1948259T3 (da)
ES (1) ES2628031T3 (da)
IL (1) IL190683A (da)
SG (1) SG184751A1 (da)
SI (1) SI1948259T1 (da)
WO (1) WO2007050902A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080026198A (ko) * 2005-06-30 2008-03-24 안트로제네시스 코포레이션 태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원
WO2007038686A2 (en) 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
WO2008021391A1 (en) * 2006-08-15 2008-02-21 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
WO2008042441A1 (en) * 2006-10-03 2008-04-10 Anthrogenesis Corporation Use of umbilical cord biomaterial for ocular surgery
WO2008060377A2 (en) 2006-10-04 2008-05-22 Anthrogenesis Corporation Placental or umbilical cord tissue compositions
CA3178363A1 (en) 2006-10-06 2008-05-15 Celularity Inc. Human placental collagen compositions, and methods of making and using the same
CA2689296C (en) * 2007-01-10 2015-11-17 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
JP5538217B2 (ja) 2007-07-10 2014-07-02 ライフセル コーポレーション 組織修復用無細胞組織基質構成体
WO2009021137A2 (en) * 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
ITUD20080058A1 (it) * 2008-03-18 2009-09-19 Thankstem S R L Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali
US20090269406A1 (en) * 2008-04-02 2009-10-29 Alyssa Panitch Therapeutic uses of biocompatible biogel compositions
US7927414B2 (en) * 2008-09-05 2011-04-19 Ethicon, Inc. Method of manufacturing acellular matrix glue
US8858698B2 (en) 2008-09-05 2014-10-14 Mentor Worldwide Llc Acellular matrix glue
CN105920582B (zh) * 2008-12-10 2020-04-14 普渡研究基金会 基于细胞渗透性肽的激酶抑制剂
WO2011017132A2 (en) 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
EP3311826B1 (en) 2011-02-14 2020-04-29 MiMedx Group, Inc. Micronized placental tissue compositions and methods for making and using the same
US20140205646A1 (en) 2011-02-14 2014-07-24 Mimedx Group, Inc. Tissue grafts modified with a cross-linking agent and method of making and using the same
WO2012149486A1 (en) * 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
EP2793745B1 (en) 2011-12-22 2019-07-31 MIMEDX Group Inc. Cross-linked dehydrated placental tissue grafts and methods for making and using the same
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
CA2880157C (en) 2012-08-15 2020-07-21 Mimedx Group, Inc. Reinforced placental tissue grafts and methods of making and using the same
US9943551B2 (en) 2012-08-15 2018-04-17 Mimedx Group, Inc. Tissue grafts composed of micronized placental tissue and methods of making and using the same
US11338063B2 (en) 2012-08-15 2022-05-24 Mimedx Group, Inc. Placental tissue grafts modified with a cross-linking agent and methods of making and using the same
US8904664B2 (en) 2012-08-15 2014-12-09 Mimedx Group, Inc. Dehydration device and methods for drying biological materials
US9180145B2 (en) 2012-10-12 2015-11-10 Mimedx Group, Inc. Compositions and methods for recruiting and localizing stem cells
US8946163B2 (en) 2012-11-19 2015-02-03 Mimedx Group, Inc. Cross-linked collagen comprising metallic anticancer agents
US9155799B2 (en) 2012-11-19 2015-10-13 Mimedx Group, Inc. Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent
US9827293B2 (en) 2013-01-17 2017-11-28 Mimedx Group, Inc. Non-surgical, localized delivery of compositions for placental growth factors
US9655948B1 (en) 2013-01-17 2017-05-23 Mimedx Group, Inc. Non-surgical, localized delivery of compositions for placental growth factors
US10517931B2 (en) 2013-01-17 2019-12-31 Mimedx Group, Inc. Non-surgical, localized delivery of compositions for placental growth factors
US10206977B1 (en) 2013-01-18 2019-02-19 Mimedx Group, Inc. Isolated placental stem cell recruiting factors
JP6545102B2 (ja) 2013-01-18 2019-07-17 ミメディクス グループ インコーポレイテッド 心病態を治療する方法
US10029030B2 (en) 2013-03-15 2018-07-24 Mimedx Group, Inc. Molded placental tissue compositions and methods of making and using the same
US9446142B2 (en) 2013-05-28 2016-09-20 Mimedx Group, Inc. Polymer chelator conjugates
US20150037434A1 (en) * 2013-08-02 2015-02-05 The Trustees Of Columbia University In The City Of New York Biomaterials derived from tissue extracellular matrix
EP3094336A4 (en) 2014-01-17 2018-02-14 MIMEDX Group Inc. Method for inducing angiogenesis
EP3185918B1 (en) 2014-08-28 2021-08-18 MiMedx Group, Inc. Collagen reinforced tissue grafts
CN107427535A (zh) * 2015-02-16 2017-12-01 纳雅康医疗有限公司 经修饰的血凝块
WO2017100600A2 (en) 2015-12-11 2017-06-15 Lifecell Corporation Methods and systems for stiffening of tissue for improved processing
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
USD856517S1 (en) 2016-06-03 2019-08-13 Musculoskeletal Transplant Foundation Asymmetric tissue graft
US10945831B2 (en) 2016-06-03 2021-03-16 Musculoskeletal Transplant Foundation Asymmetric tissue graft
USD895812S1 (en) 2018-09-07 2020-09-08 Musculoskeletal Transplant Foundation Soft tissue repair graft
US10813743B2 (en) 2018-09-07 2020-10-27 Musculoskeletal Transplant Foundation Soft tissue repair grafts and processes for preparing and using same
CN114306746B (zh) * 2021-12-20 2023-04-14 四川大学 一种抗凝血脱细胞真皮基质的制备方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
US5804178A (en) 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US6309635B1 (en) 1986-11-20 2001-10-30 Children's Medical Center Corp. Seeding parenchymal cells into compression resistant porous scaffold after vascularizing in vivo
US5567612A (en) 1986-11-20 1996-10-22 Massachusetts Institute Of Technology Genitourinary cell-matrix structure for implantation into a human and a method of making
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US20020115165A1 (en) 1986-11-20 2002-08-22 Stein James E. Prevascularzed polymeric implants for organ transplantation
ATE119787T1 (de) 1989-04-25 1995-04-15 Childrens Medical Center Implantaten für grosse mengen von zellen auf polymerische matrizen.
US5102407A (en) * 1990-03-13 1992-04-07 Miles Inc. Blood separation system
US5135851A (en) 1990-05-08 1992-08-04 Kajander E Olavi Culture and detection method for sterile-filterable autonomously replicating biological particles
DE69229252T2 (de) 1991-08-16 1999-12-16 Merck & Co Inc DNS, welche das Interleukin-1B-Vorläufer-Converting-Enzym kodiert
WO1993007913A1 (en) 1991-10-24 1993-04-29 Children's Medical Center Corporation Neomorphogenesis of urological structures in vivo from cell culture
WO1993008850A1 (en) 1991-10-30 1993-05-13 Massachusetts Institute Of Technology Prevascularized polymeric implants for organ transplantation
US5610753A (en) 1991-12-12 1997-03-11 Eastman Kodak Company Optical design of laser scanner to reduce thermal sensitivity
US5800537A (en) 1992-08-07 1998-09-01 Tissue Engineering, Inc. Method and construct for producing graft tissue from an extracellular matrix
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US6689608B1 (en) 1993-02-01 2004-02-10 Massachusetts Institute Of Technology Porous biodegradable polymeric materials for cell transplantation
WO1994025079A1 (en) 1993-04-23 1994-11-10 Massachusetts Institute Of Technology Porous biodegradable polymeric materials for cell transplantation
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US6176874B1 (en) 1993-10-18 2001-01-23 Masschusetts Institute Of Technology Vascularized tissue regeneration matrices formed by solid free form fabrication techniques
ES2219660T3 (es) 1994-03-14 2004-12-01 Cryolife, Inc Metodos de preparacion de tejidos para implantacion.
AU3145795A (en) 1994-07-26 1996-02-22 Children's Medical Center Corporation Fibrin-cell suspension for construction of new tissue
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6281015B1 (en) 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US5855610A (en) 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US5741685A (en) 1995-06-07 1998-04-21 Children's Medical Center Corporation Parenchymal cells packaged in immunoprotective tissue for implantation
JPH09122225A (ja) 1995-10-31 1997-05-13 Bio Eng Lab:Kk 医用材料の原料膜材およびその製造方法
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
WO1997017038A1 (en) 1995-11-09 1997-05-15 University Of Massachusetts Tissue re-surfacing with hydrogel-cell compositions
WO1999025396A2 (en) 1997-11-17 1999-05-27 The Regents Of The University Of Michigan Hybrid tissues for tissue engineering
US6371992B1 (en) 1997-12-19 2002-04-16 The Regents Of The University Of California Acellular matrix grafts: preparation and use
US6171610B1 (en) 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
US6027744A (en) 1998-04-24 2000-02-22 University Of Massachusetts Medical Center Guided development and support of hydrogel-cell compositions
US6432710B1 (en) 1998-05-22 2002-08-13 Isolagen Technologies, Inc. Compositions for regenerating tissue that has deteriorated, and methods for using such compositions
US6387367B1 (en) 1998-05-29 2002-05-14 Osiris Therapeutics, Inc. Human mesenchymal stem cells
ES2249928T3 (es) 1998-11-19 2006-04-01 Organogenesis Inc. Constructos de tejido manipulado mediante bioingenieria y metodos para producirlos y utilizarlos.
US20020022592A1 (en) 1999-03-31 2002-02-21 Michael Detmar Delivery of thrombospondin from implantable tissue matrices
US7759113B2 (en) 1999-04-30 2010-07-20 The General Hospital Corporation Fabrication of tissue lamina using microfabricated two-dimensional molds
JP2002542883A (ja) 1999-04-30 2002-12-17 マサチューセッツ ジェネラル ホスピタル 微細加工した２次元鋳型を用いる血管新生組織の加工
WO2001045765A1 (en) 1999-12-22 2001-06-28 Acell, Inc. Tissue regenerative composition
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
WO2001049113A1 (en) 1999-12-30 2001-07-12 University Of Massachusetts Spore-like cells and uses thereof
WO2001055212A2 (en) 2000-01-27 2001-08-02 The General Hospital Corporation Delivery of therapeutic biological from implantable tissue matrices
US7776021B2 (en) 2000-04-28 2010-08-17 The Charles Stark Draper Laboratory Micromachined bilayer unit for filtration of small molecules
US20020151050A1 (en) 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
US6899915B2 (en) 2000-11-29 2005-05-31 President And Fellows Of Harvard College Methods and compositions for culturing a biological tooth
WO2002053193A2 (en) 2001-01-02 2002-07-11 The Charles Stark Draper Laboratory, Inc. Tissue engineering of three-dimensional vascularized using microfabricated polymer assembly technology
WO2002067867A2 (en) 2001-02-23 2002-09-06 The University Of Pittsburgh Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
US6995013B2 (en) 2002-07-08 2006-02-07 Biomed Solutions, Llc Cell-scaffold composition containing five layers
WO2003076564A2 (en) 2001-05-16 2003-09-18 The General Hospital Corporation Tissue-engineered organs
JP2005500304A (ja) * 2001-06-21 2005-01-06 アルタス バイオロジックス インコーポレイテッド 球状タンパク質粒子およびそれらの作製方法および使用方法
CA2463850C (en) 2001-10-18 2013-03-26 Lifecell Corporation Remodeling of tissues and organs
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US6987987B1 (en) 2002-07-03 2006-01-17 Sprint Spectrum L.P. Method and system for providing advanced notice of cost to access web content
EP1538196A1 (en) * 2002-08-23 2005-06-08 ASAHI MEDICAL Co., Ltd. Fibrin-containing composition
WO2004026115A2 (en) 2002-09-23 2004-04-01 The General Hospital Corporation Theree-dimensional construct for the design and fabrication of physiological fluidic networks
US7402319B2 (en) 2002-09-27 2008-07-22 Board Of Regents, The University Of Texas System Cell-free tissue replacement for tissue engineering
AU2003275326A1 (en) 2002-09-30 2004-04-23 Massachussetts Eye And Ear Infirmary In vitro culture of tissue structures
AU2003277385A1 (en) 2002-10-16 2004-05-04 The General Hospital Corporation Cell-seeded tissue-engineered polymers for treatment of intracranial aneurysms
WO2004034890A2 (en) 2002-10-17 2004-04-29 Vacanti, Joseph, P. Biological scaffolding material
US7351430B2 (en) * 2002-11-06 2008-04-01 Uluru Inc. Shape-retentive hydrogel particle aggregates and their uses
DE10256848A1 (de) 2002-12-04 2004-07-08 Sibylle Latza Verfahren und Vorrichtung zum Separieren von Vollblut unter Schwerkraft in ein Erythrozytenkonzentrat und Plasma
CN1509770A (zh) 2002-12-24 2004-07-07 捷 杨 无细胞基质移植物的制备及应用
WO2004065616A2 (en) 2003-01-16 2004-08-05 The General Hospital Corporation Use of three-dimensional microfabricated tissue engineered systems for pharmacologic applications
US20050123520A1 (en) 2003-05-05 2005-06-09 Eavey Roland D. Generation of living tissue in vivo using a mold
US7960166B2 (en) 2003-05-21 2011-06-14 The General Hospital Corporation Microfabricated compositions and processes for engineering tissues containing multiple cell types
WO2005060396A2 (en) 2003-08-18 2005-07-07 The General Hospital Corporation Nanotopographic compositions and methods for cellular organization in tissue engineered structures
WO2005018429A2 (en) 2003-08-20 2005-03-03 Histogenics Corporation Acellular matrix implanted into an articular cartilage or osteochondral lesion protected with a biodegradable polymer modified to have extended polymerization time and methods for preparation and use thereof
US8043614B2 (en) 2004-03-09 2011-10-25 Ahlfors Jan-Eric W Autogenic living scaffolds and living tissue matrices: methods and uses thereof
US7316822B2 (en) 2003-11-26 2008-01-08 Ethicon, Inc. Conformable tissue repair implant capable of injection delivery
WO2006020240A2 (en) 2004-07-16 2006-02-23 The Forsyth Institute Methods and compositions for bioengineering a tooth
DE102005030614B4 (de) * 2005-06-30 2014-05-08 Biotissue Ag Zellfreies Transplantat, dessen Verwendung, Verfahren zu dessen Herstellung, dabei hergestellte Matrix mit Gel und Verfahren zur Herstellung dieser Matrix mit Gel
EP2384205A1 (en) * 2009-01-02 2011-11-09 Ramot at Tel-Aviv University Ltd. Fibrin and fibrinogen matrices and uses of same

Also Published As

Publication number Publication date
CA2627288C (en) 2015-12-15
US20070202189A1 (en) 2007-08-30
AU2006305989A1 (en) 2007-05-03
IL190683A0 (en) 2008-11-03
IL190683A (en) 2015-01-29
WO2007050902A1 (en) 2007-05-03
US8268361B2 (en) 2012-09-18
EP1948259B1 (en) 2017-03-22
JP2017190336A (ja) 2017-10-19
US20130136796A1 (en) 2013-05-30
SI1948259T1 (sl) 2017-07-31
JP6696940B2 (ja) 2020-05-20
US9314420B2 (en) 2016-04-19
JP2016026184A (ja) 2016-02-12
JP2020007377A (ja) 2020-01-16
EP1948259A1 (en) 2008-07-30
CA2627288A1 (en) 2007-05-03
US10272029B2 (en) 2019-04-30
SG184751A1 (en) 2012-10-30
ES2628031T3 (es) 2017-08-01
AU2006305989B2 (en) 2013-10-24
US20170157290A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
DK1948259T3 (da) Acellulær bioabsorberbare vævsregenereringsmatrixer produceret ved inkubering af acellulære blodprodukter
Sierpinski et al. The use of keratin biomaterials derived from human hair for the promotion of rapid regeneration of peripheral nerves
Zhang et al. A nerve graft constructed with xenogeneic acellular nerve matrix and autologous adipose-derived mesenchymal stem cells
ES2790300T3 (es) Métodos y medios para ingeniería de tejidos blandos
US20180125897A1 (en) Decellularized Adipose Cell Growth Scaffold
CA2743871C (en) Extracellular matrix compositions for the treatment of cancer
EP2995326A1 (en) Hybrid gel containing particulate decellularized tissue
Astaneh et al. Chitosan/gelatin hydrogel and endometrial stem cells with subsequent atorvastatin injection impact in regenerating spinal cord tissue
US20210046125A1 (en) Decellularized tissues, hydrogels thereof, and uses thereof
Zhu et al. Bioorthogonal DOPA-NGF activated tissue engineering microunits for recovery from traumatic brain injury by microenvironment regulation
KR101488716B1 (ko) 치조골 재생용 키트
JP2009513269A (ja) 無細胞血液産物をインキュベートすることによって生成される無細胞、生体吸収性の組織再生マトリックス
US20190275206A1 (en) Tissue implants and uses thereof
CN113577108B (zh) 一种多功能胶原支架、其制备方法与应用
JP5890364B6 (ja) 無細胞血液産物をインキュベートすることによって生成される無細胞、生体吸収性の組織再生マトリックス
AU2013237667A1 (en) Acellular bioabsorbable tissue regeneration matrices produced by incubating acellular blood products
Jinno et al. Extracorporeal high-pressure therapy (EHPT) for malignant melanoma consisting of simultaneous tumor eradication and autologous dermal substitute preparation
Guo et al. Evaluation of benefits and risks of immunosuppressive drugs in biomaterial-based neural progenitor cell transplantation for spinal cord injury repair
Piening Development and Characterization of a Decellularized Neuroinhibitory Scaffold Containing Matrix Bound Nanovesicles
Ji et al. A simple method to isolate structurally and chemically intact brain vascular basement membrane for neural regeneration following traumatic brain injury
Hill Regeneration of peripheral nerves using neuroinductive biomaterial scaffolds
Schurig Tissue engineering for reconstructing the central dopaminergic nigro-striatal pathway in Parkinson’s disease: Cutting edge cell culture studies